CORE ADANIPORTS+0.24% BIRET-0.24% BRIGADE-0.85% DLF-1.17% EMBASSY+1.10% GMRAIRPORT+0.00% GODREJPROP+0.19% IRB+3.46% LODHA-0.98% LT-1.76% MAHLIFE-1.64% MINDSPACE-1.39% NCC-0.64% OBEROIRLTY-0.14% PHOENIXLTD+0.11% PRESTIGE-0.22% SOBHA+0.95% as of 2026-08-26 18:44 UTC

The Annexure

Desk› Healthcare› Marksans Pharma Ltd

Marksans Pharma Ltd

BSE 524404 MARKSANS INE750C01026
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Filing rhythm · 61 trading days

32 filings · 9 material · busiest 2026-07-03

What it files

General6 Newspaper Publication4 Analyst / Investor Meet3 Concall Transcript2 Press Release2 AGM / EGM2 Board Outcome1 Results1

Filings

32 in the window

  1. 26 August 2026

    General

    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find attached disclosure on ESG rating

    Company Update / General View filing →

  2. 20 August 2026

    Concall Transcript

    Earnings Call Transcript

    Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results

    Company Update / Earnings Call Transcript View filing →

  3. 13 August 2026

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication for Unaudited Financial Results for the quarter ended June 30, 2026

    Company Update / Newspaper Publication View filing →

  4. 13 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results

    Company Update / Analyst / Investor Meet View filing →

  5. 12 August 2026

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On 12 August 2026

    The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026

    Board Meeting / Outcome of Board Meeting View filing →

  6. 12 August 2026

    Results

    Result For The Quarter Ended June 30, 2026

    The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 2026

    Result / Financial Results View filing →

  7. 12 August 2026

    Investor Presentation

    Investor Presentation

    Investor Presentation Q1 FY 27

    Company Update / Investor Presentation View filing →

  8. 12 August 2026

    Press Release

    Press Release / Media Release

    Press Release for Financial Results Q1 FY 27

    Company Update / Press Release / Media Release View filing →

  9. 6 August 2026

    Newspaper Publication

    Newspaper Publication

    Please find attached newspaper publication for Annual General Meeting Notice

    Company Update / Newspaper Publication View filing →

  10. 4 August 2026

    AGM / EGM

    Shareholders Annual General Meeting To Be Held On August 27, 2026

    Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026

    AGM/EGM / AGM View filing →

  11. 4 August 2026

    Annual Report

    Reg. 34 (1) Annual Report.

    Please find attached herewith the Annual Report for the Financial Year 2025-26

    Others / Reg. 34 (1) Annual Report View filing →

  12. 4 August 2026

    BRSR

    Business Responsibility and Sustainability Reporting (BRSR)

    Please find enclosed the BRSR

    Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

  13. 3 August 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of schedule for Q1FY27 Earnings Conference Call

    Company Update / Analyst / Investor Meet View filing →

  14. 31 July 2026

    Board Meeting

    Board Meeting Intimation for Board Meeting Intimation For Declaration Of Quarterly Results For The Quarter Ended June 30, 2026

    Marksans Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Quarterly Results For The Quarter ....

    Board Meeting / Board Meeting View filing →

  15. 30 July 2026

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication for AGM Intimation

    Company Update / Newspaper Publication View filing →

  16. 20 July 2026

    General

    Updates

    Update on acquisition of 100 percent share capital of ABCnow GmbH.

    Company Update / General View filing →

  17. 17 July 2026

    General

    DISCLOSURE REGARDING SECOND 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"

    Second 100 Day Campaign - "Saksham Niveshak" Phase IV

    Company Update / General View filing →

  18. 10 July 2026

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  19. 8 July 2026

    Press Release

    Press Release / Media Release

    Marksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Company namely ABCnow GmbH

    Company Update / Press Release / Media Release View filing →

  20. 3 July 2026

    Outcome

    Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Annual General Meeting Related Matters

    The Board in its meeting approved the AGM related matters and fixed 27 August 2026 as the AGM of the Company

    Others / Outcome without intimation View filing →

  21. 3 July 2026

    Record Date

    The Board Fixed 20 August 2026 As The Record Date For Ascertaining The Members Of The Company For Payment Of Dividend.

    20 August 2026 is fixed as Record Date for payment of dividend.

    Corp. Action / Record Date View filing →

  22. 3 July 2026

    AGM / EGM

    The Annual General Meeting Of The Marksans Pharma Limited Is Scheduled To Be Held On 27 August 2026.

    The Board of Directors of Marksans Pharma Limited in its meeting held on 3 July 2026 fixed 27 August 2026 as the Annual General Meeting.

    AGM/EGM / AGM View filing →

  23. 3 July 2026

    Corporate Action

    Dividend Updates

    The Board of Directors of Marksans Pharma Limited fixed 20 August 2026 as the Record Date for payment of dividend.

    Corp Action / Dividend Updates View filing →

  24. 3 July 2026

    Dividend

    Date of payment of Dividend

    Pl find attached announcement related to record date for payment of dividend, AGM date and dividend payment date.

    Corp Action / Date of payment of Dividend View filing →

  25. 26 June 2026

    General

    Updates

    Machine Readable Form/Legible copy of Financial Results

    Company Update / General View filing →

  26. 26 June 2026

    Trading Window

    Closure of Trading Window

    Intimation of Closure of Trading Window for the quarter ended June 30, 2026

    Insider Trading / SAST / Closure of Trading Window View filing →

  27. 23 June 2026

    General

    DISCLOSURE REGARDING SECOND 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"

    Campaign for KYC and other related updations and shareholders engagement to prevent transfer of unclaimed dividend to IEPF

    Company Update / General View filing →

  28. 16 June 2026

    General

    Updates

    Update on acquisition of QliniQ B.V.

    Company Update / General View filing →

  29. 9 June 2026

    Credit Rating

    Credit Rating

    India Ratings and Research has revised the outlook for the Company's bank loan facilities to Positive from Stable

    Company Update / Credit Rating View filing →

  30. 8 June 2026

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of schedule for Virtual Investors Conference

    Company Update / Analyst / Investor Meet View filing →

  31. 3 June 2026

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication regarding Second 100 day Campaign- "Saksham Niveshak"

    Company Update / Newspaper Publication View filing →

  32. 3 June 2026

    Concall Transcript

    Earnings Call Transcript

    Marksans Pharma Limited submits Transcripts of Investors/Analyst meet on Q4 FY 26 Audited Financial Results

    Company Update / Earnings Call Transcript View filing →